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Persistent Inflammation and Angiogenesis during
Wound Healing in K14-Directed Hoxb13 Transgenic
Mice
Judith A. Mack1,2 and Edward V. Maytin1,2
Chronic, nonhealing wounds and inadequate tissue repair characterized by excessive fibrosis continue to have
a considerable negative effect on health and quality of life. Understanding the molecular events required for
adequate healing, including the transcriptional control of wound repair, will be important for the development
of future therapies. We previously showed that loss of Hoxb13 from murine skin results in enhanced cutaneous
wound healing, suggesting that Hoxb13 has a negative effect on wound repair. To test this, we generated skin-
specific Hoxb13 transgenic (TG) mice that overexpress Hoxb13 in the basal layer of the epidermis by the human
keratin 14 promoter. Using these mice, we evaluated the effects of Hoxb13 overexpression on cutaneous wound
healing. Transgenic wounds were characterized by persistence of the fibrin clot and prolonged inflammation.
Notably, neutrophils, which had cleared from wild-type wounds, were still pronounced in TG wounds. Marked
epidermal hyperplasia was observed at TG wound edges, and dermal vessels were grossly abnormal compared
with wild-type mice. Both vascular endothelial growth factor and tumor necrosis factor-a were upregulated in
Hoxb13 TG skin. Together, our results identify Hoxb13 as a potential important clinical target in wound healing
and other pathologies characterized by abnormal or excessive inflammation, angiogenesis, or epidermal proliferation.
Journal of Investigative Dermatology (2010) 130, 856–865; doi:10.1038/jid.2009.305; published online 17 September 2009
INTRODUCTION
Wound healing is an elaborate process that requires precise
orchestration and communication between keratinoctyes,
fibroblasts, endothelial cells, inflammatory cells, and the
extracellular matrix (Gailit and Clark, 1994; Arbiser, 1996;
Santoro and Gaudino, 2005; Eming et al., 2007; Raja et al.,
2007). Disruption of these interactions can severely inhibit
repair. Nonhealing wounds (or abnormal healing charac-
terized by excessive scarring) continue to be a major health
problem, so understanding the molecular events required for
adequate healing is a major research focus. During the past
several years, much has been learned about the regulation
of wound healing by growth factors and cytokines (Wahl
et al., 1989; McKay and Leigh, 1991; Bryan et al., 2005). By
contrast, much less is known about transcriptional regulation
at the wound site (Schafer and Werner, 2007). One group
of regulators that has recently been shown to have important
roles in wound repair is the Hox family of transcription factors.
Hox proteins are best known for their key roles as
regulators of axial and organ patterning during embryonic
development (Krumlauf, 1994; Manak and Scott, 1994;
Martinez and Amemiya, 2002; Hombria and Lovegrove,
2003; Grier et al., 2005). To date, 39 Hox genes have been
identified in the vertebrate genome. In mouse and humans,
they reside in four complexes (A–D in humans; a–d in mice)
located on four different chromosomes. On the basis of
sequence similarity and position, corresponding genes in
the four complexes can be aligned with each other in 13
paralogous groups whose functions are often overlapping. In
addition to their early developmental roles, it has become
increasingly evident over the past several years that Hox
gene activity is important in adult tissues (Morgan, 2006). The
majority of the known 39 Hox genes have been reported to
be expressed in adult skin (Detmer et al., 1993; Chang et al.,
1998; Stelnicki et al., 1998b). It is in this organ that the
functional requirements for Hox gene activity in adults have
been most studied, particularly in the area of cutaneous
wound repair. Members of the Hox3 paralogus group have
been shown to function as positive regulators of angiogenesis,
to promote endothelial as well as epithelial migration, and to
enhance collagen deposition in the wound bed (Myers et al.,
2000; Mace et al., 2005). In contrast, HoxA5 and HoxD10
have been shown to inhibit angiogenesis (Myers et al., 2002;
Rhoads et al., 2005).
We have previously shown that another member of the
Hox family, Hoxb13, also influences cutaneous wound healing
(Mack et al., 2003). Hoxb13 is expressed in unperturbed fetal
and adult skin (Stelnicki et al., 1998b), but is significantly
downregulated in fetal wounds that heal without a scar
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compared with adult wounds (Stelnicki et al., 1998a). This
result suggested that downregulating Hoxb13 in adult wounds
could lead to a more effective repair. To that end, we
determined that cutaneous wounds in Hoxb13 knockout mice
healed faster and with less scar compared with wounds in wild-
type mice (Mack et al., 2003). We further determined that
Hoxb13 knockout skin contained significantly higher levels of
hyaluronan, a high molecular weight glycosaminoglycan that
has been implicated as an important factor in fetal scarless
wound healing (McCallion and Ferguson, 1996).
Here, to further examine the effects of Hoxb13 on
cutaneous wound repair, we have generated Hoxb13
transgenic (TG) mice, using the human keratin 14 promoter
(K14-Hoxb13 mice). This promoter is highly active in the
basal layer of stratified squamous epithelia and in the outer
root sheath of hair follicles (Vassar et al., 1989). Young adult
Hoxb13 TG mice were fertile with no apparent skin
abnormalities. However, when wounded, they demonstrated
delayed healing, exemplified by persistence of the wound
eschar, a protracted inflammatory response, enlarged vessels,
and grossly abnormal epidermal histology. We further
determined that vascular endothelial growth factor (VEGF)
and tumor necrosis factor-a (TNF-a) are upregulated in
K14-Hoxb13 TG skin, suggesting that these molecules may be
responsible in part for the atypical angiogenesis and inflamma-
tion, respectively, observed in TG wounds. Together, these data
indicate that overexpression of Hoxb13 has a negative effect
on wound healing and implicate Hoxb13 as a possible tran-
scriptional activator of VEGF and/or TNF-a.
RESULTS
Generation of K14-Hoxb13 TG mice
The Hoxb13 cDNA with a 50 Flag-tag epitope was inserted
into a targeting vector containing sequence from the human
keratin 14 (K14) promoter (Figure 1a). In mice, the human
K14 promoter is highly active in the basal layer of the
epidermis and the outer root sheath of the hair follicle,
matching that of endogenous K14 (Vassar et al., 1989). To test
for expression, the K14-Flag-Hoxb13 vector (Figure 1a) or
K14 vector alone was transiently transfected into a rat
epidermal keratinocyte cell line, which exhibits robust K14
expression (data not shown). Western blot analysis showed
a strong band of the expected 34kDa size after staining with
anti-Flag or anti-Hoxb13 antibody (Figure 1b, left panels).
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Figure 1. Generation and verification of K14-Hoxb13 transgenic (TG) mice. (a) Schematic of the K14-Hoxb13 transgene construct. Primers 1 and 3 identify
the Hoxb13 transgene; Primers 2 and 3 identify both the transgene and the endogenous Hoxb13 gene. (b) Verification of transgene expression by western blot
(left) and immunostaining (right) of transiently transfected rat epidermal keratinocytes with anti-Flag and anti-Hoxb13 antibodies; anti-actin, internal loading
control. (c) PCR genotyping of selected founder mice; lanes 3 and 4 are positive for the Hoxb13 transgene (upper bands). The lower band indicates both
the transgene and endogenous Hoxb13. (d) Western blot of Hoxb13 TG skin extracts with anti-Flag antibody; anti-keratin-14, internal loading control.
The lower band (dashed box) represents the Flag-Hoxb13 fusion protein; note its complete absence in the lane from wild-type littermate (WTLM) skin.
NS, nonspecific bands. A similar sized NS band was also seen in the western blot shown in panel b. Transgenic strains 1 and 3 (TG1, TG3) express relatively high
levels of transgene product compared with strains 2, 4, and 5. (e) Immunostaining of Hoxb13 TG strain 3 (TG3) with anti-Flag antibody. Transgene product is
detected in the nuclei of basal keratinocytes of the epidermis and outer root sheath of hair follicles (white arrowheads). Scale bar¼ 100mm.
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Immunohistochemical analysis demonstrated nuclear staining
with both antibodies (Figure 1b, right panels). TG founders
were identified by PCR using forward Flag and reverse
Hoxb13 primers (see Figure 1a). Figure 1c shows a sample
genotyping; the upper band represents the transgene. Six
independent TG lines were established and designated K14-
Hoxb13 TG strains nos. 1–6. Western blot analysis was
performed on skin protein extracts from TG mice and wild-
type littermates (WTLM) using anti-Flag antibody (Figure 1d).
The antibody recognized Flag-Hoxb13 (Figure 1d, boxed
region) as well as a nonspecific band also observed in pro-
tein extracts from transfected cells (Figure 1b). K14-Hoxb13
TG strains 1 and 3 were relatively high expressors compared
with TG strains 2, 4, and 5. The absence of a signal in the
WTLM samples confirmed the specificity of the Flag-epitope
detection. K14-Hoxb13 TG strain 6 was also a high expressor
(data not shown). Skin sections from K14-Hoxb13 TG strain
3 stained with anti-Flag antibody showed signal in the nuclei
of the epidermal basal layer and outer root sheath of the hair
follicle (Figure 1e, arrowheads). No signal was obtained in
sections from WTLM. K14-Hoxb13 TG mice appeared healthy.
There were no differences in skin morphology between TG
mice and WTLM by gross inspection, by histological staining
with hematoxylin and eosin, or by immunostaining for epidermal
keratin 10 and 14 (data not shown).
Wound healing is delayed in response to Hoxb13
overexpression in the epidermis
To evaluate the effects of Hoxb13 overexpression after injury,
we created 5-mm diameter, full-thickness excisional wounds
on each of the six K14-Hoxb13 TG strains and their WTLM
and monitored the wounds for 11 days. Typical results are
illustrated in Figure 2a. By day 11 post-wounding, the fibrin
clot (crust) had resolved and the wound was completely
closed in the WTLM. In contrast, the wound area of the TG
mouse was still covered by a large fibrin crust that remained
tightly adhered to the skin. TG strains 1 and 6 (the other two
high expressors) also retained a large crust at day 11 post-
wounding (data not shown). To compare the efficacy of
healing in the low Hoxb13 expressors and the high Hoxb13
expressors, we measured the area of the wound/crust over
time (Figure 2b). The involved area was larger in all Hoxb13
overexpressors relative to WTLM up to 7 days post-wound-
ing. A large crust still covered the wounds of all high Hoxb13
expressors at day 11 post-wounding. In a follow-up study,
the adherent crusts in Hoxb13 high expressors persisted until
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Figure 2. Transgenic (TG) mice expressing high levels of epidermal Hoxb13 exhibit abnormal wound healing compared with low expressors or wild-type
littermates (WTLMs). Following general anesthesia and shaving of the dorsal hair, a single 5-mm full-thickness excisional wound was made on the upper
back of six pairs of mice (a K14-Hoxb13 TG mouse and its respective WTLM) derived from six different founder strains. The wounds were photographed every
other day. (a) Wounds from TG strain 3 (a high Hoxb13 expressor) are shown, along with its WTLM. Note that in the WTLM at day 11 post-wounding, the crust
had resolved and the wound was completely closed. By contrast, a large fibrin crust persisted at the wound site in the Hoxb13 TG mouse. (b) At the times
indicated, the area of the wound and crust was measured using photography and digital analysis. Data from three strains that weakly expressed the Hoxb13
transgene were pooled (low expressors, left graph, open circle), as were their corresponding WTLM (left graph, closed circle). The strains that strongly expressed
the transgene were grouped in a similar manner (high expressors, right graph). Note that for all times up to day 7, all Hoxb13 TG mice showed a larger wound-
crust area than the WTLM. This difference persisted beyond day 7 and was statistically significant in the high-expressing Hoxb13 TG mice; *Po0.05, **Po0.01,
and ***Po0.0005.
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days 14–15 (data not shown). These findings suggest that
wound healing is substantially delayed as a result of Hoxb13
overexpression in the epidermis.
Wound morphology is grossly abnormal in mice expressing high
levels of Hoxb13
For histological analysis, we stained 11-day-old wound
sections with hematoxylin and eosin (Figure 3). WTLM
wounds (Figure 3a and b) were characterized by a defined
region of granulation tissue (1), a closed and moderately
hyperplastic epidermis (2), and a loosely woven stratum
corneum (SC, 3). The wounds of low Hoxb13 expressors (TG
strain 4 is shown here, Figure 3c) displayed a healthy granu-
lation bed, but in comparison with the WTLM contained an
increased number of inflammatory cells (4, area within
dashed white line). In addition, epidermal irregularities were
occasionally noted such as increased acanthosis and small
compact areas of hyperkeratosis (5). The wound histology of
the high Hoxb13 expressors (Figure 3d and e) was severely
abnormal compared with the WTLM and the low Hoxb13
expressors. The large and tightly adhered eschar present at
the wound site (corresponding to morphology of Figure 2a)
contained numerous inflammatory cells (6). The epidermis
was highly irregular, with central atrophic areas (7) and
severely hyperplastic regions with elongated ridges at the
wound edge (8). A well-defined region of granulation tissue
was absent in the wounds of the high Hoxb13 expressors
(Figure 3d and e) as compared with WTLM (Figure 3a and b).
Within the dermal area of the healing wounds, the number of
inflammatory cells was grossly increased in high Hoxb13
expressing TG mice relative to WTLM (9, area within
white dashed line). Together, these findings indicate that
overexpression of Hoxb13 in the epidermis is detrimental to
wound healing.
Overexpression of Hoxb13 enhances and prolongs the wound
inflammatory response
To better characterize the increased inflammatory cell
infiltrates observed in the wounds of K14-Hoxb13 TG mice,
skin sections from 11-day-old excisional wounds were
stained for neutrophils, macrophages, and mast cells
(Figure 4). A neutrophil-specific antibody revealed occasional
neutrophils in the wound beds of WTLM (Figure 4a and c) or
low Hoxb13 expressors (Figure 4b). In contrast, wound beds
of high Hoxb13 expressors contained large numbers of
neutrophils (Figure 4d), comprising a sixfold elevation over
WTLM or low Hoxb13 expressors (Figure 4e). Macrophages,
detected by antibody F4/80, were increased by approxi-
mately twofold in the Hoxb13 expressors relative to WTLM
or to low Hoxb13 expressors (Figure 4f-j). Mast cells at and
adjacent to the wound site were evaluated by toluidine blue
staining (Figure 4k and l; open arrowheads). There was
no difference in mast cell numbers between low Hoxb13
expressors and matched WTLM (Figures 4m, left). However,
in high Hoxb13 expressors, mast cells were B3-fold more
abundant than in their WTLM (Figure 4m, right). Overall,
these results indicate that overexpression of Hoxb13 in the
epidermis dramatically prolongs the inflammatory response
in wounds.
Transgenic mice expressing high levels of Hoxb13 exhibit
atypical vessel biology
Hematoxylin and eosin stained wounds of high Hoxb13-
expressing mice appeared highly vascularized compared
with WTLM. To examine vessel subtypes, wound sections
were stained with antisera to platelet endothelial cell adhe-
sion molecule-1 for blood vessels (PECAM-1, Figure 5a and b)
or lymphatic vessel endothelial receptor-1 (Figure 5c and d)
for lymphatics (Banerji et al., 1999). Blood and lymphatic
vessels were quantified by microscopy and computer-assisted
image analysis (Table 1). Uninjured skin showed a slight
trend toward higher vessel density in Hoxb13 overexpressors
(Table 1, first row). Wounding led to a large increase in
numbers of blood vessels by 11 days, and both the size (area)
and length of these vessels were increased two- to threefold
in Hoxb13 overexpressors versus WTLM (Figure 5a and b;
Table 1, rows 1, 2). Lymphatic vessels were significantly
influenced by the expression of the Hoxb13 transgene in both
Figure 3. Hoxb13 overexpression in the epidermis leads to a highly abnormal
wound morphology. Hematoxylin and eosin stains of 11-day-old excisional
wounds are illustrated as follows: (a, b), wild-type littermates (WTLMs);
(c), a low-expressing Hoxb13 transgenic (TG) mouse; (d, e), high-expressing
Hoxb13 TG mice. The founder strains are indicated. (a, b) At 11 days post-
wounding, a healthy bed of granulation tissue (1) and a completely intact
epidermis (2) with a loosely woven stratum corneum (3) was observed in
WTLM wounds. (c) Wounds from a low-expressing TG mouse contained a
granulation bed that was healthy but contained increased inflammatory cells
(4; area within the dashed region), along with epidermal abnormalities such
as increased acanthosis and compact hyperkeratosis (5). (d, e) Wounds from
Hoxb13 high-overexpressors remained covered with a dense eschar that
contained numerous polymorphonuclear cells (6). Epidermal morphology at
those wound sites showed epidermal atrophy overlying the wound bed (7),
and irregular epidermal hyperplasia with elongated ridges at the wound edges
(8). An increased inflammatory cell infiltrate was observed in the dermal
portion of the wound bed in the TG mice (9). Scale bar¼100 mm.
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unwounded and wounded skin (Figure 5c and d; Table 1,
rows 4–6). The total density of lymph vessels in skin was
significantly increased in the K14-Hoxb13 TG mice (threefold
in unwounded skin, 13-fold in wounded skin) through a
combination of increased number of vessels and enlargement
of their lumens. Thus, overexpression of Hoxb13 has a
marked effect on both angiogenesis and lymphangiogenesis.
VEGF and TNF-a are upregulated in K14-Hoxb13 TG skin
To determine molecular mechanisms for the increased
angiogenesis and inflammation in K14-Hoxb13 TG wounded
skin, we examined the expression of VEGF and TNF-a, two
molecules known to have key roles in angiogenesis and
inflammation, respectively. Overexpression of VEGF in
murine skin by the K14-promoter (K14-VEGF) has been
reported to upregulate both angiogenesis and lymphangio-
genesis (Nagy et al., 2002; Xia et al., 2003; Hong et al.,
2004). TNF-a has been shown to be a potent chemoattractant
for neutrophils (Sayers et al., 1988; Lukacs et al., 1995;
Widegren et al., 2008). We evaluated VEGF and TNF-a
expression in both unwounded and wounded TG (high
expressor) and WTLM skin by western blot (Figure 6a). In
unwounded skin, bands of 43 and 25 kDa, corresponding to
VEGF and TNF-a, respectively, were detected, which were
markedly more intense in the TG lanes (black asterisks).
Compared with the GAPDH loading controls, there was a
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Figure 4. Wounds in Hoxb13 high-expressor mice contain significantly more inflammatory cells than in wild-type mice. Eleven-day-old full-thickness excisional
wounds stained with the following antibodies: (a–d) neutrophil-specific, RB6-8C5; (f–i) macrophage-specific, F4/80; (k, l) toluidine blue, for mast cells
(arrowheads). Scale bar¼ 100mm. Mouse transgenic (TG) strains 4 and 5 (low expressors) and strains 1 and 3 (high expressors) are illustrated in the panels, while
the graphs (e, j, m) show aggregate data for all strains. P-values are indicated for significant differences. NS, not significant. Results represent mean±SEM
from at least nine optical fields each from the low Hoxb13 expressors, high Hoxb13 expressors, and wild-type littermates (WTLMs).
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threefold increase in VEGF levels and a 4.5-fold increase in
TNF-a levels in TG unwounded skin compared with WTLM
(Figure 6b). In lysates from wounded skin at 7 days, the
intensity of the VEGF 43kDa band was similar between TG
and WTLM. However, new bands of B58 and 80 kDa were
present that were stronger in the TG lanes (arrows). We believe
that these larger bands may represent post-translationally
modified VEGF (see Discussion section). As in unwounded
skin, the 25kDa TNF-a band was significantly more intense in
lysates from 7-day TG wounds (black asterisks). The elevated
VEGF and TNF-a expression in K14-Hoxb13 TG mice suggests
that these molecules are responsible in part for the increased
vascularity and inflammation, respectively, observed in TG
unwounded and/or wounded skin.
DISCUSSION
We have previously shown that loss of Hoxb13 from skin
results in enhanced cutaneous wound healing (Mack et al.,
2003). In this study we demonstrate that overexpression of
Hoxb13 in the epidermis (1) has a deleterious effect on wound
healing, (2) results in protracted inflammation and atypical
vessel remodeling, and (3) is associated with an upregulation
of both VEGF and TNF-a in the skin of K14-Hoxb13 TG mice.
Hox genes are best known for their highly conserved roles
in embryonic patterning (Krumlauf, 1994; Manak and Scott,
1994). We are just beginning to elucidate their functions in
adult tissues. Despite their abundance in both fetal and adult
tissues, relatively few direct targets of Hox transcriptional
activity have been identified. Of those that have been
characterized, several have been assigned biological roles
that are important in wound healing, including angiogenesis
(Wu et al., 2003; Bruhl et al., 2004), cell migration (Daftary
et al., 2002), and inflammation (Shi et al., 2001; Bandyo-
padhyay et al., 2007; Mori et al., 2008). In the context of
cutaneous wound healing, HoxD3 has been shown to induce
the expression of type 1 collagen in wounds (Hansen et al.,
2003) and HoxA3 and D3 have been reported to promote
angiogenesis in murine skin following wounding (Myers
et al., 2000; Mace et al., 2005).
Vascular endothelial growth factor is a major mediator of
angiogenesis (Ferrara and Davis-Smyth, 1997). In this study
Wildtype
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Figure 5. Blood vessels and lymphatic vessels are enlarged in the skin of
K14-Hoxb13 transgenic (TG) mice expressing high levels of the transgene.
Staining of frozen sections from 11-day-old full-thickness excisional wounds
in K14-Hoxb13 TG3 or matched wild-type littermates, using antisera to the
following: (a, b) platelet endothelial cell adhesion molecule-1 (blood vessels);
(c, d) lymphatic vessel endothelial receptor-1 (lymphatic vessels). All images
are taken from the middle of the wound bed. Dotted lines, epidermal–dermal
junction. Arrows, lymphatic vessels. Scale bar¼ 100mm.
Table 1. Summary of blood vessels and lymphatics in normal and wounded skin of Hoxb13 mice
Unwounded skin1 Wounded skin (11 days)1
Wildtype Transgenic Increase Wildtype Transgenic Increase
Mean±SD (n) Mean±SD (n) (fold) Mean±SD (n) Mean±SD (n) (fold)
Angiogenesis (PECAM-1)
Blood vessel area (% of dermal area) 1.5±0.66 (9) 2.4±1.3 (9)* 1.6 2.5±1.3 (6) 8.7±5.0 (6)** 3.5
Blood vessel length (mm) ND ND ND 43.2±6.8 (8) 92.3±11.8 (8)**** 2.1
Number of vessels (vesselsmm2) 13±3.1 (9) 16±9.2 (9) 1.2 150±49 (8) 132±25 (8) 0.9
Lymphangiogenesis (LYVE1-1)
Lymph vessel area (% of dermal area)2 0.23±0.01 (13) 0.64±0.13 (14)**** 2.8 0.22±0.23 (12) 2.90±1.3 (12)**** 13.2
Lumen size (mm2) 23±28 (13) 149±147 (14)*** 6.5 73±95 (12) 402±527 (12)*** 5.5
Number of vessels (vesselsmm2) 8.8±3.4 (13) 13±4.5 (14)*** 1.5 8.7±7.7 (8) 35±14 (8)**** 4.1
1The data are from unperturbed skin or from skin at 11 days post-wounding. Transgenic mice and wild-type littermate from strains 3 and 6 were used for
these experiments.
2The upper dermis, above the bulge region of hair follicles, was analyzed. (n), number of fields (images) that were analyzed.
P-values for comparison of transgenic versus wild type are indicated as superscripts:
*Po0.05.
**Po0.01.
***Po0.005.
****Po0.0005.
ND, not done.
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we show that VEGF is a potential target of Hoxb13. In normal
mice, VEGF is expressed at low levels in the epidermis, but is
upregulated in wounded epidermis for 2–3 days post-injury
(Brown et al., 1992). Epidermal VEGF is thought to promote
dermal angiogenesis by a paracrine response. As cited earlier,
angiogeneisis and lymphangiogenesis are upregulated in
K14-VEGF skin/wounds (Nagy et al., 2002; Xia et al., 2003;
Hong et al., 2004). The murine K14 promoter is still very
active at day 11 post-wounding (data not shown), indicating
that K14-Hoxb13 expression is almost certainly high at this
time point. Therefore, it is likely that Hoxb13-induced VEGF
is in part responsible for the increased angiogenesis and
lymphangiogenesis observed in the wound bed of TG mice.
However, we cannot rule out the involvement of other factors
such as VEGF-C or VEGF-D, which have been identified as
critical cytokines responsible for generating the lymphatic
vascular system (Jussila and Alitalo, 2002; Oliver and
Detmar, 2002).
Our western blots showed a significant increase in the
intensity of the VEGF 43 kDa band in unwounded K14-
Hoxb13 TG skin (Figure 6). This was not observed in lysates
from wounded skin. However, we detected bands of a higher
molecular weight than that predicted by amino-acid
sequence alone that were more intense in lysates from TG
wounds. We postulate that these represent alternate forms of
VEGF. VEGF can be modified post-translationally through
such events as ADP-ribosylation, glycosylation, and heparin
binding (Ghani et al., 2003; Brandner et al., 2006), all of
which can have a marked influence on its biological activity.
We are not yet certain what influence Hoxb13-induced
expression of VEGF is having on wound healing per se. It has
been reported that epidermal VEGF is required for the
development of hyperplasia in response to a sustained barrier
disruption injury (Elias et al., 2008). This suggests that the
marked epidermal hyperplasia observed at the wound edges
of K14-Hoxb13 TG wounds (see Figure 3) may be due in part
to abnormally high levels of epidermal VEGF. Interestingly,
Wilgus et al. (2008) recently reported that addition of VEGF
to fetal wounds that normally heal in a scarless manner
results in increased vascularity and a scarring phenotype,
while neutralization of VEGF in adult wounds reduced
vascularity and scar formation. We have preliminary data
indicating increased scarring and fibrosis in K14-Hoxb13 TG
wounds compared with the wounds of WTLM (data not
shown). Therefore, it is possible that increased and prolonged
expression of VEGF in TG wounds may be contributing to
excessive scarring.
Another important feature of K14-Hoxb13 TG mice is the
upregulation of the proinflammatory cytokine TNF-a. In normal
healthy skin, TNF-a is expressed at low levels in epidermal kera-
tinocytes (Strickland et al., 1997). In injured or diseased tissue,
TNF-a levels are greatly augmented by activated macrophages
(Chen and Goeddel, 2002) and mast cells (Gordon and Galli,
1990). TNF-a levels are significantly higher in both TG
unwounded and wounded skin. We have found no evidence
of increased inflammation in unwounded TG skin (data not
shown), suggesting that the source of the increased TNF-a is
epidermal in nature. In wounded TG skin, higher TNF-a levels
are most likely due to the increased and protracted presence
of macrophages and mast cells at the wound site. However,
we cannot rule out the possibility that Hoxb13 is abnormally
upregulating epidermal TNF-a in response to wounding.
TNF-a is a potent inducer of neutrophil adhesion
(Bevilacqua et al., 1987; Gotsch et al., 1994) and infiltration
into damaged tissues (Lukacs et al., 1995; Widegren et al.,
2008). Several studies have demonstrated that addition of
exogenous TNF-a to wounds is detrimental to wound healing
(Rapala et al., 1991; Salomon et al., 1991; Buck et al., 1996).
In addition, mice deficient for the tumor necrosis factor
receptor p55 (TNF-Rp55), which is normally upregulated
following cutaneous wounding, show accelerated wound
healing in association with markedly reduced recruitment of
neutrophils and macrophages (Mori et al., 2002). These data
suggest that increased TNF-a in K14-Hoxb13 TG wounds,
interacting with TNF-Rp55, is significantly contributing to the
exacerbated inflammatory response and delayed healing.
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Figure 6. VEGF and tumor necrosis factor-a (TNF-a) are differentially
upregulated in the skin of Hoxb13 transgenic (TG) mice. (a) Western blot of
protein extracts from unwounded skin and from 7-day full-thickness excisional
wounds stained with antibodies to VEGF, TNF-a, and glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) as an internal control. Locations of
molecular weight (MW) markers, in kDa, are shown on the right. The VEGF
antibody detects a 43 kDa band in unwounded and wounded skin, but the
intensity of this band is much greater in the K14-Hoxb13 TG unwounded
lanes (asterisks) as compared with the strain-matched wild-type littermates
(WT). In wounded skin, high-MW VEGF bands are observed that are
significantly more intense in the TG lanes (arrows). The TNF-a antibody
detects a 25 kDa band that is significantly more intense in the K14-Hoxb13
TG unwounded and wounded lanes. (b) Densiometric analyses of the 43 kDa
VEGF, 25 kDa TNF-a, and GAPDH western blot signals from unwounded skin
(n¼3 independent K14-Hoxb13 TG mice and three matching WTLM).
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A notable phenotype of high expressing K14-Hoxb13 TG
excisional wounds is the persistence of the fibrin clot, which
normally resolved by approximately 7 days post-wounding in
WTLM, but remained large and tightly adherent in Hoxb13
high expressors for as long as 15 days. Both VEGF and
TNF-a are strong inducers of vascular permeability, allowing
vessels to leak plasma proteins and promote fibrin deposition
(Nawroth et al., 1988; Brett et al., 1989; Keck et al., 1989;
Senger et al., 1990). The combined activity of high levels of
VEGF and TNF-a in TG wounds may be responsible for the
persistence of the fibrin clot. Alternatively, it is also possible
that the clot may be lacking substances required for its lysis.
Fibrin clots harbor growth factors and cytokines (Clark,
2003). On the basis of this observation, it is conceivable that
K14-Hoxb13 TG wounds are being subjected to prolonged
exposures of growth factors and/or cytokines, which may be
deleterious to the wound environment.
The mechanisms by which Hoxb13 upregulates VEGF and
TNF-a are not currently clear. As a transcription factor,
Hoxb13 could be promoting expression by direct binding
and activation of their promoters. Both the VEGF and TNF-a
promoter contain potential Hoxb13 consensus binding sites
(data not shown). Alternatively, Hoxb13 could be indirectly
influencing their expression through the regulation of up-
stream genes. In the case of VEGF, one potential candidate is
hypoxic-inducible factor-1, a master regulator of VEGF
expression (Dery et al., 2005). Interestingly, TNF-a can also
induce VEGF expression in a hypoxic-inducible factor-1-
dependent manner.
In conclusion, we have shown that overexpression of
Hoxb13 in the murine epidermis through the K14 promoter
results in abnormal wound healing, a prolonged inflamma-
tory response, vascular enlargement, and upregulation of
VEGF and TNF-a. The latter two molecules have a central
role not only in wound healing but also in tumor growth, and
have been associated with skin pathologies such as psoriasis
(Kristensen et al., 1993; Xia et al., 2003). We previously
reported that overexpression of Hoxb13 in an organotypic
epidermal model resulted in many tissue characteristics
reminiscent of psoriasis (Mack et al., 2005). Interestingly, it
should also be noted that Hoxb13 is upregulated in cancer
(Cantile et al., 2003; Svingen and Tonissen, 2003; Lopez
et al., 2006; Yamashita et al., 2006) and promotes ovarian
cancer progression (Miao et al., 2007). As part of our ongoing
study, we will also investigate the expression of other key
molecules important in cutaneous healing and disease such
as basic fibroblast growth factor and transforming growth
factor-b (Arbiser et al., 1998; Li et al., 2004). Together, our
current data suggest that Hoxb13 may be an important
clinical target in wound healing and in other pathological
skin conditions that involve excessive inflammation, angio-
genesis, and epidermal hyperproliferation.
MATERIALS AND METHODS
Generation and identification of K14-Hoxb13 TG mice
The full-length mouse Hoxb13 cDNA was obtained from Open
Biosystems (Huntsville, AL). An N-terminal Flag-tagged Hoxb13 with
flanking Xba sites and a Kozak sequence directly upstream of the
Flag tag was generated by PCR using the following primers: Forward
50-CTCTAGAGCCACCATGGATTACAAGGATGACGACGATAAGG
AGCCCGGCAATTATGCC-30; Reverse 50-AGTGCTCAACAGAGCTC
TAGATAGAA-30 and subcloned into the pCR2.1 vector using the
TOPO cloning Kit (Invitrogen, Carlsbad, CA). The Flag-Hoxb13
sequence was then subcloned into the Xba site of the human K14
promoter vector (kindly provided by Dr Xiao-Jing Wang, University
of Colorado, Denver). TG mice were generated at the Case TG and
Targeting Facility (Case Western Reserve University, Cleveland, OH)
and identified by PCR analysis of tail DNA. The Flag-Hoxb13
transgene was identified using a Flag-specific forward primer, 50-GG
ATTACAAGGATGACGACGATAAGG-30 and a Hoxb13-specific
reverse primer, 50-AGGTTCTTCAGAACCGTAATGGA-30. The PCR
product positive for the Flag-Hoxb13 transgene was approximately
1083bp. The mice were maintained as hemizygotes.
Preparation of nuclear extracts
Rat epidermal keratinocytes were transiently transfected with 5mg of the
K14 promoter vector alone or with 5mg of the K14-Flag-Hoxb13 vector
using Gene Porter (Genlantis, San Diego, CA) and incubated at 37 1C in
5% CO2 for 48hours. Cells were then washed in cold phosphate-
buffered saline, scraped and resuspended in 1ml of phosphate-buffered
saline, and centrifuged. The pellet was resuspended in cold hypotonic
buffer (10mM Hepes, pH 7.9, 10mM Kcl, 0.1mM EDTA, 0.1mM EGTA,
and 1mM dithiothreitol), incubated on ice for 15minutes followed by
the addition of 25ml of 1% NP-40, and vortexed for 10 seconds. Lysed
cells were spun for 1minute at full speed and the pellet resuspended in
50ml of a cold hypertonic buffer (20mM Hepes, pH 7.9, 0.4mM NaCl,
0.1mM EDTA, 0.1mM EGTA, 20% glycerol, 1mM dithiothreitol, and
1mM phenylmethylsulfonyl fluoride), followed by shaking for 15min-
utes at 4 1C. The lysate was then spun at full speed for 5minutes, and
the supernatant containing nuclear proteins transferred to a clean tube.
Protein concentration was determined by Bradford Assay (Bio-Rad,
Hercules, CA) and the samples were stored at 80 1C.
Preparation of skin protein lysates
Full-thickness skin specimens were placed in Brij lysis buffer (1ml of
1 M Tris, 0.4ml of 0.5 M EDTA, 3ml of 5 M NaCl, 8.75ml of 10% Brij
97, 1.25ml of 10% NP40, diluted to 100ml with H2O) or Cell Lysis
Buffer from Ray Bio (Norcross, GA) each containing a protease
inhibitor cocktail (Sigma-Aldrich, St Louis, MO), homogenized, and
briefly sonicated. Samples were then centrifuged at 13,000 r.p.m. for
10minutes at 4 1C and the supernatant transferred to new tubes
on ice. Protein concentrations were determined by Bradford Assay
(Bio-Rad) and the samples were stored at 80 1C.
Western blot analysis
Proteins were electrophoresed on NuPAGE 4–12% Bis-Tris gels
(Invitrogen) and blotted according to the standard protocol. Blots
were blocked for 1 hour at room temperature (blocking buffer: 5%
milk, 50mM Tris pH 7.5, 150mM NaCl), and incubated overnight
with the following antibodies: mouse monoclonal Hoxb13 (1:200;
Santa Cruz Biotechnology, Santa Cruz, CA), mouse monoclonal Flag
(1:500, Sigma-Aldrich), rabbit anti-mouse b-actin (1:500; Santa Cruz
Biotechnology), rabbit anti-mouse keratin-14 (1:2,000; Covance,
Denver, PA), rabbit anti-mouse VEGF (1mgml1; Abcam, Cambridge,
MA), rat monoclonal TNF-a (BioXCell, West Lebanon, NH) or rabbit
anti-mouse GAPDH (1:500; Santa Cruz Biotechnology) followed by
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a 1–2 hours incubation with the appropriate horseradish peroxidase-
conjugated secondary (1:10,000; Sigma-Aldrich). Signal was devel-
oped using ECL or ECL Plus Western Blotting Detection System
(GE Healthcare, Waukesha, WI).
Wounding protocols
The Cleveland Clinic Institutional Animal Care and Use Committee
(IACUC) approved all animal procedures. At the time of this study,
K14-Hoxb13 TGs were backcrossed to C57BL/6 four times. Sex
matched K14-Hoxb13 TGs and WTLMs at 8–12 weeks were
anesthetized with an intraperitoneal injection of Pentobarbitol
(40–85mg kg1; Ovation Pharmaceutical, Deerfield, IL), shaved on
the dorsal back, and the area wiped down with 70% alcohol. Each
mouse received a 5-mm diameter full-thickness excisional wound on
the upper dorsal back using iris scissors. Wounds were left open to
the air. All wounded animals were housed in individual cages for the
duration of the study or until the wound was harvested.
Histological and immunohistochemical analysis
Fixed skin samples were processed, embedded, and cut into 5 mm
sections. Slides were baked overnight at 42 1C and stained with
hematoxylin and eosin using a standard protocol. Primary antibodies
utilized for immunohistochemistry were rat anti-mouse RB6–8C5 for
neutrophils (1:100; a gift from Robert Fairchild, Cleveland Clinic,
OH), rat anti-mouse F4/80 for macrophages (1:50; Serotec, Raleigh,
NC), rabbit anti-OctA (1:100; Santa Cruz; reacts with the Flag
epitope), rabbit-anti-mouse K14 (1:1,000; Covance), rabbit-anti
mouse K10 (1:500; Covance), biotinlyated rabbit polyclonal to
lymphatic vessel endothelial receptor-1 (1mgml1; Abcam), and
biotinylated rat anti-mouse PECAM-1/CD31 (1:100; BD Bioscience,
San Jose, CA). For staining, detection, and mounting, the ABC
staining system for rat or rabbit primary antibodies (Santa Cruz
Biotechnology) was used with detection by DAB/HRP/H2O2 with
mounting in Permount (Vector, Burlingame, CA) or streptavidin-Cy3
(Jackson Immunoresearch, West Grove, PA) followed by mounting
in Vectashield (Vector).
Statistics
All statistical analyses were performed using the Student’s t-test, and
a P-value less than 0.05 was considered statistically significant.
Values were presented as means±SD or SE.
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